دور الأميودارون الوريدي في تدبير نوب تسرع القلب الوصلي فوق البطيني عند الأطفال

الملخص EN

Background &Objective: At the time adenosine became the first choice in the management of junctional SVT in children during the last 10 - 15 years, intravenous amiodarone became available in Damascus University, children hospital.

Thus, intravenous amiodarone became the first choice in treatment of this arrhythmia in the hospital instead of digoxine.

Verapamil and beta blockers which were in the hospital despite their risks for many past decades when amiodarone was used worldwide.

The purpose of this study is to recognize the efficacy and safety of intravenous amiodarone for short-term treatment of Junctional SVT cases in young patients in Damascus university, children hospital.

Materials and Methods: This descriptive prospective study involved 19 cases with Junctional SVT admitted to Damascus University, Children Hospital over one year during 2013.

Diagnosis of Junctional SVT cases and the treatment with intravenous amiodarone were put according to the especial criteria of Junctional SVT done by European Resuscitation Council Guidelines for Resuscitation 2010 and Pediatric advanced life support Guidelines.

The efficacy and safety of intravenous amiodarone for short-term treatment of 19 Junctional SVT cases in 13 children were evaluated.

Age ranged from12 days to 9 years, the average age was 4.1 years, 63.1% were < 2 years, 5 from 13 patients had structural congenital heart diseases, and 3 had myocarditis.

The average heart rate was 245 ± 30 beats / min.

The treatment with intravenous amiodarone was effective and successful in 17 (89.5%) of 19 Junctional SVT cases with early successful response from the first dose in 14 cases (73.7%).

Complete response was obtained after an average time 45 minutes from the beginning of the intravenous therapy.

There were no dangerous side effects, and there was no recurrence of the Junctional SVT during the short-term treatment as well.

No Death in this study was attributed to amiodarone therapy or Junctional SVT case itself .

Conclusion: Intravenous Amiodarone is a good choice, safe and highly effective as a first-line drug for short-term treatment in children with Junctional supraventricular tachycardia (SVT) in Damascus University Children Hospital.

with mild probable side effects in the absence of Adenosine.

Close monitoring is required in all settings because of its potential and significant adverse effects.